Annals of Surgical Oncology

, Volume 21, Issue 6, pp 1884–1890 | Cite as

Risk Factors for Recurrence After Therapeutic Lateral Neck Dissection for Primary Papillary Thyroid Cancer

  • Su-jin Kim
  • Seog Yun Park
  • You Jin Lee
  • Eun Kyung Lee
  • Seok-ki Kim
  • Tae Hyun Kim
  • Yu-Seog Jung
  • Junsun Ryu
  • Jun Pyo Myong
  • Ki-Wook Chung
Endocrine Tumors



Lateral lymph node metastasis is an important prognostic factor and is predictive of tumor recurrence and cause-specific survival in patients with papillary thyroid cancer (PTC). However, the factors predicting recurrence and clinical outcomes after therapeutic lateral neck dissection are not well established. The aims of this study were to evaluate the incidence, pattern, and factors predictive of PTC recurrence after therapeutic lateral neck dissection.

Materials and Methods

The records of 126 consecutive patients who underwent total thyroidectomy with therapeutic lateral neck dissection for primary PTC at the National Cancer Center were retrospectively reviewed. The factors predictive of recurrence were determined using both univariate and multivariate analyses considering several clinicopathologic variables.


The median follow-up period was 61.2 months, during which 22 patients (17.5 %) experienced recurrence with 1 death (0.8 %) due to disease. Locoregional recurrence and distant metastasis were found in 20 cases (15.9 %) and 2 cases (1.6 %), respectively. Male gender, aggressive histology, number of lymph node metastases, initial level of T4-off Tg per ng/mL, and ATA risk categories (high risk) were independent risk factors for recurrence. Of note, initial T4-off Tg levels greater than 4.2 ng/mL showed highest sensitivity and specificity in predicting recurrence.


These results provide useful information regarding the clinical outcomes after therapeutic lateral neck dissection for primary PTC and can be used to identify at-risk patients who need aggressive treatment and intensive surveillance for postoperative recurrence.


Papillary Thyroid Cancer Locoregional Recurrence Extrathyroidal Extension BRAFV600E Mutation Lateral Lymph Node Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by a research grant from the National Cancer Center (No. 0810100-1).

Supplementary material

10434_2014_3507_MOESM1_ESM.tiff (207 kb)
ROC analysis to determine an optimal off Tg level recurrence after therapeutic lateral neck dissection that maximized sensitivity and specificity, i.e., the point on the ROC curve farthest from chance. (TIFF 207 kb)


  1. 1.
    Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck. 1996;18:127–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26:22–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Rossi RL, Cady B, Silverman ML, Wool MS, Horner TA. Current results of conservative surgery for differentiated thyroid carcinoma. World J Surg. 1986;10:612–22.PubMedCrossRefGoogle Scholar
  4. 4.
    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.PubMedCrossRefGoogle Scholar
  5. 5.
    GH Sakorafas, D Sampanis, M Safioleas. Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. Surg Oncol. 2010;19;e57–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Lee YS, Kim SW, Kim SW, Kim SK, Kang HS, Lee ES, et al. Extent of routine central lymph node dissection with small papillary thyroid carcinoma. World J Surg. 2007;31:1954–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Stack BC, Ferris R, Goldenberg D, Haymart M, Shaha A, Sheth S, Sosa JA, Tufano RP. American thyroid association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid. 2012;22:1–8.CrossRefGoogle Scholar
  8. 8.
    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.Google Scholar
  9. 9.
    Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinoma of the thyroid. Endocr J. 2009;56:177–92.PubMedCrossRefGoogle Scholar
  10. 10.
    Ito Y, Miyauchi A, Jikuzono T, Higashiyama T, Takamura Y, Miya A, et al. Risk factors contributing to a poor prognosis of papillary thyroid carcinoma; validity of UICC/AJCC TNM classification and stage grouping. World J Surg. 2007; 31:838–48.PubMedCrossRefGoogle Scholar
  11. 11.
    Leboulleux S, Rubino C, Baudin, Caillou B, Hartl DM, Bidart JM, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005;71:731–4.PubMedGoogle Scholar
  13. 13.
    Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMedCrossRefGoogle Scholar
  14. 14.
    Lim I, Kim SK, Hwang SS, Kim SW, Chung KW, Kang HS, et al. Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer. Ann Nucl Med. 2012;26:777–86.PubMedCrossRefGoogle Scholar
  15. 15.
    Foreset VI, Clark JR, Ebrahimi A, Cho EA, Sneddon L, Gao K, et al. Central compartment dissection in thyroid papillary carcinoma. Ann Surg. 2011;253:123–30.CrossRefGoogle Scholar
  16. 16.
    Ricarte-Filho J, Ganly I, Rivera M, Katabi N, Fu W, Shaha A, et al. Papillary thyroid carcinoma with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid. 2012;22:575–84.PubMedCrossRefGoogle Scholar
  17. 17.
    Siegel R, Naishadham D, Jermal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Ito Y, Kudo T, Takamura Y, Kobayashi K, Miya A, Miyauchi A. Lymph node recurrence in patients with N1b papillary thyroid carcinoma who underwent unilateral therapeutic modified radical neck dissection. World J Surg. 2012;26:593–7.CrossRefGoogle Scholar
  19. 19.
    Shah PK, Shah KK, Karakousis GC, Reinke CE, Kelz RR, Fraker DL. Regional recurrence after lymphadenectomy for clinically evident lymph node metastases form papillary thyroid cancer: a cohort study. Ann Surg Oncol. 2012;19:1453–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Albuja-Cruz MB, Thorson CM, Allan BJ, Lew JI, Rodgers SE. Number of lymph nodes removed during modified radical neck dissection for papillary thyroid cancer does not influence lateral neck recurrence. Surgery. 2012;152:1177–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Caron NR, Tan TT, Ogilvie JB, Reiff ES, Kebebew E, Duh QY, et al. Selective modified radical neck dissection for papillary thyroid cancer-is level I, II, and V dissection always necessary? World J Surg. 2006;30:833–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Mazzaferi EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–63.CrossRefGoogle Scholar
  23. 23.
    Lin JD, Hsueh C, Chao TC. Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome. Thyroid. 2009; 19:1053–1059.PubMedCrossRefGoogle Scholar
  24. 24.
    Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381:1058–69.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Su-jin Kim
    • 1
    • 2
    • 3
  • Seog Yun Park
    • 4
  • You Jin Lee
    • 4
  • Eun Kyung Lee
    • 4
  • Seok-ki Kim
    • 4
  • Tae Hyun Kim
    • 4
  • Yu-Seog Jung
    • 4
  • Junsun Ryu
    • 4
  • Jun Pyo Myong
    • 5
  • Ki-Wook Chung
    • 4
    • 6
  1. 1.Department of SurgerySeoul National University Hospital & College of MedicineSeoulKorea
  2. 2.Cancer Research InstituteSeoul National University College of MedicineSeoulKorea
  3. 3.Division of Surgery, Thyroid CenterSeoul National University Cancer HospitalSeoulKorea
  4. 4.Center for Thyroid CancerNational Cancer CenterGoyangKorea
  5. 5.Department of Occupational and Environmental Medicine, Seoul St. Mary’s HospitalThe Catholic UniversitySeoulKorea
  6. 6.Department of SurgeryAsan Medical CenterSeoulKorea

Personalised recommendations